NCT00274092View on ClinicalTrials.gov

Efficacy and Safety of Tiotropium Inhalation Capsules and Atrovent MDI in Patients With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL
Enrollment

132

Participants

Timeline

Start Date

September 30, 2002

Primary Completion Date

October 31, 2003

Study Completion Date

October 31, 2003

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

tiotropium inhalation capsules (18 mcg once daily)

DRUG

Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients

Trial Locations (6)

100

National Taiwan University Hospital, Taipei

114

Tri-Service General Hospital, Taipei

407

Veterans General Hospital, Taichung

813

Kaohsiung Veterans General Hospital, Kaohsiung City

12217

Veterans General Hospital, Taipei

Unknown

Kaohsiung Medical University Chung-Ho Memorial Hospital, Kaohsiung City

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY